Intuitive Surgical (NASDAQ: ISRG ) has become one of the most debated stories in the health-care industry in recent weeks. In addition to negative reports from the investment and medical communities in recent months, the company behind the da Vinci robotic surgery platform has fallen prey to Bloomberg's recent discovery of an FDA "inquiry" into topics including procedure safety and surgeon training. However, as Brenton Flynn highlights in the following video, one thing that hasn't received as much attention as it deserves is the human element of surgery. User error will always be a variable at work, and Brenton thinks it's a big feather in Intuitive's cap.
Are stories of Intuitive's demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize, or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.